The Irvine, California-based firm said its "Revolution" system offer recovery rates of 70 to 90 percent across a wide range of liquid sample volumes.
The researchers hope to eventually develop a point-of-care assay to detect conditions that lead to high-risk pregnancies before symptoms occur.
The Royal Oaks, Michigan-based firm anticipates launching the assay — which currently analyzes 214 genes for prostate cancer risk — for research-use-only applications in H2 2020.
The researchers believe that combining liquid and tissue biopsy can improve diagnostic and therapeutic options for cancer patients with acquired drug resistance mutations.
NanoView will develop custom antibody-based assays on its ExoView platform to identify EVs containing biomarkers potentially linked to the neurological disorders.
UK researchers have detected RNA biomarkers in extracellular vesicles that are potentially correlated to aggressive mesenchymal glioblastoma cells.
Researchers have launched a startup called Fluxus to commercialize a platform based on the optofluidic chip for molecular analysis.
The firm is developing a biomarker panel to detect mutations in mesenchymal cells, with the goal of guiding drug treatment and improving earlier patient intervention.
Researchers developed a microfluidic device that combines antibody-based cell capture and disulfide cleavage for downstream microRNA detection.
The firm will begin a verification study later this month using its cell-sorting platform and molecular analysis tool on patients with a pelvic mass scheduled for surgery.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.